NCT07717710 Ivabradine for Heart Rate Reduction During Exercise in Healthy Adults
| NCT ID | NCT07717710 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of British Columbia |
| Condition | Healthy Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-10-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2026-10-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
During exercise, working muscles require more oxygen. The heart meets this demand in two ways: by beating faster (heart rate) and by pumping more blood with each beat (stroke volume). Heart rate increases steadily with exercise intensity until exhaustion, but the amount of blood pumped with each beat tends to plateau at moderate intensities. Why the amount of blood pumped with each beat becomes limited before heart rate, however, is not well understood. Studying these mechanisms is difficult because most drugs that lower heart rate also affect how strongly the heart pumps, making it hard to separate the two effects. One medication that can help with this is ivabradine, which is used to treat people with heart disease who have high resting heart rates. It slows the heart rate without changing how strongly the heart pumps. This study will investigate whether ivabradine lowers heart rate during exercise in healthy younger and older adults, and whether a higher dose lowers heart rate more. The results will help us better understand how heart rate influences the heart's ability to supply oxygen to the body during exercise, and what limits the ability to exercise as people age. Participants will: * Attend three visits at SportsCardiologyBC in Vancouver * Complete a cycling exercise test at each visit to measure heart rate and how hard they can exercise * Take ivabradine (a heart-rate-lowering medication) before the exercise test at Visits 2 and 3 (a lower dose at Visit 2 and a higher dose at Visit 3) * Be monitored for side effects including slow heart rate, visual symptoms, and headache.
Eligibility Criteria
Inclusion Criteria: * Healthy males and females aged 19-39 years, and 60-79 years * Engaging in regular aerobic exercise (e.g., running, cycling, swimming, hiking, field, ice, or racquet sports) at least once per week Exclusion Criteria: * History of any cardiovascular condition, including hypertension * Use of any chronic medication * History of any respiratory condition, including asthma * Smoking, including cannabis or vaping in the past year * History of diabetes mellitus, cancer, hepatic, renal or any other chronic illness * Seated blood pressure ≥130/90 or \<100/60 mmHg * Body mass index \<20 or \>32 kg/m2 * Non-sinus rhythm or abnormalities on 12-lead electrocardiogram (ECG) * Pregnant, breastfeeding, or women of childbearing potential not using appropriate contraception * Current or recent (past year) participation in \>150 minutes per week of moderate-vigorous intensity exercise (to avoid endurance training-related bradycardia) * Any condition that prevents vigorous exercise from being performed safely * Seated resting heart rate \<60 beats per minute * Prolonged QT interval (e.g., long QT syndrome) * Sick sinus syndrome, sino-atrial block or third-degree atrio-ventricular block * Use of strong cytochrome P450 (CYP3A4) inhibitors (e.g., nirmatrelvir and ritonavir, ketoconazole), which can increase ivabradine levels in the blood to potentially unsafe levels * Use of verapamil or diltiazem, which are moderate CYP3A4 inhibitors and also lower heart rate, posing a risk of excessive bradycardia when combined with ivabradine * Lactose intolerance, as ivabradine contains lactose * Known allergy/hypersensitivity to ivabradine or to any ingredient in the formulation or component of the container
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07717710 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 79 Years, studying Healthy Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07717710 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07717710 currently recruiting?
Yes, NCT07717710 is actively recruiting participants. Contact the research team at stephen.wright@ubc.ca for enrollment information.
Where is the NCT07717710 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT07717710 clinical trial?
NCT07717710 is sponsored by University of British Columbia. The trial plans to enroll 20 participants.